Eli Lilly will raise the list price in the UK of its weight-loss and type 2 diabetes treatment Mounjaro by 170% to be in line with other European markets, the U.S. drugmaker said on Thursday. Lilly launched Mounjaro in the UK in February last year,

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.

Eli Lilly will increase the UK price of its Mounjaro treatment by 170% to match European markets. Despite Novo Nordisk's initial market lead with Wegovy, Mounjaro's sales have surged. The NHS will maintain access to the drug despite the price hike,